Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Sujuan Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-1116-3840; OpenAlex author ID A5100952228. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 9

  1. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  2. KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Co-author DOI 10.1016/j.ccell.2023.07.002↗
  3. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. First author DOI 10.1016/j.ccell.2022.06.011↗
  4. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-1484↗
  5. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2021.02.007↗
  6. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. First author DOI 10.1016/j.celrep.2021.108990↗
  7. Generation and testing of clinical-grade exosomes for pancreatic cancer. Co-author DOI 10.1172/jci.insight.99263↗
  8. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Co-author DOI 10.1038/nature22341↗
  9. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Co-author DOI 10.1080/15384047.2017.1281499↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Raghu Kalluri · 9 shared papers, 2017–2025 · strength 1.05
  2. Kathleen M. McAndrews · 6 shared papers, 2018–2025 · strength 0.77
  3. Krishnan K. Mahadevan · 3 shared papers, 2022–2025 · strength 0.45
  4. Yang Chen · 3 shared papers, 2021–2022 · strength 0.40
  5. Anirban Maitra · 3 shared papers, 2018–2025 · strength 0.38
  6. Huamin Wang · 2 shared papers, 2021–2022 · strength 0.28
  7. Julienne L. Carstens · 2 shared papers, 2021–2022 · strength 0.26
  8. Elizabeth J. Shpall · 2 shared papers, 2018–2025 · strength 0.25
  9. Mayela Carolina Mendt Vilchez · 2 shared papers, 2018–2025 · strength 0.25
  10. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.18
  11. Valerie S. Kalluri · 1 shared paper, 2025 · strength 0.18
  12. Gauri Rajani Varadhachary · 1 shared paper, 2025 · strength 0.18
  13. Brandon George Smaglo · 1 shared paper, 2025 · strength 0.18
  14. Shubham Pant · 1 shared paper, 2025 · strength 0.18
  15. Jiha Kim · 1 shared paper, 2021 · strength 0.14
  16. Sushrut Kamerkar · 2 shared papers, 2017–2018 · strength 0.14
  17. Sónia A. Melo · 2 shared papers, 2017 · strength 0.13
  18. Timothy Paul Heffernan · 1 shared paper, 2023 · strength 0.13
  19. Paola A. Guerrero · 1 shared paper, 2023 · strength 0.13
  20. Haoqiang Ying · 1 shared paper, 2023 · strength 0.13
  21. Michael P. Kim · 1 shared paper, 2023 · strength 0.13
  22. Xiaofeng Zheng · 1 shared paper, 2021 · strength 0.13
  23. Andrew D. Rhim · 1 shared paper, 2021 · strength 0.13
  24. Xiaofeng Zheng · 1 shared paper, 2022 · strength 0.13
  25. Huamin Wang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.